相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy
Michael Carr et al.
MOLECULAR CANCER RESEARCH (2022)
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
Alessia Anastasia et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Structural insights into inhibitor regulation of the DNA repair protein DNA-PKcs
Shikang Liang et al.
NATURE (2022)
Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648
Cho R. Hong et al.
RADIOTHERAPY AND ONCOLOGY (2022)
DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathway
Liu Liu et al.
SCIENCE SIGNALING (2022)
Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
Sushmita B. Gordhandas et al.
SCIENTIFIC REPORTS (2022)
Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk
Forough Alemi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2022)
Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer
Mary Smithson et al.
NEOPLASIA (2022)
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
Mark T. J. van Bussel et al.
BRITISH JOURNAL OF CANCER (2021)
Structure of an activated DNA-PK and its implications for NHEJ
Xuemin Chen et al.
MOLECULAR CELL (2021)
Activation of homologous recombination in G1 preserves centromeric integrity
Duygu Yilmaz et al.
NATURE (2021)
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth
Rosalin Mishra et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
Analia Azaro et al.
INVESTIGATIONAL NEW DRUGS (2021)
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
Marjorie G. Zauderer et al.
INVESTIGATIONAL NEW DRUGS (2021)
Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
Kyoko Nakamura et al.
CLINICAL CANCER RESEARCH (2021)
Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures
David Sehnal et al.
NUCLEIC ACIDS RESEARCH (2021)
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells
Olivia S. Chao et al.
PROSTATE (2021)
DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia
Eric Haines et al.
SCIENTIFIC REPORTS (2021)
HPV16 E6 enhances the radiosensitivity in HPV-positive human head and neck squamous cell carcinoma by regulating the miR-27a-3p/SMG1 axis
Dan Long et al.
INFECTIOUS AGENTS AND CANCER (2021)
DNA-Dependent Protein Kinase Catalytic Subunit: The Sensor for DNA Double-Strand Breaks Structurally and Functionally Related to Ataxia Telangiectasia Mutated
Yoshihisa Matsumoto et al.
GENES (2021)
DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer
Manni Wang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy
Catherine E. Willoughby et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
Maria M. Rubinstein et al.
CANCER (2020)
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
Frederick W. Goldberg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Vanillin derivative VND3207 activates DNA-PKcs conferring protection against radiation-induced intestinal epithelial cells injury in vitro and in vivo
Ming Li et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2020)
DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
Michael Carr et al.
FRONTIERS IN ONCOLOGY (2020)
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
Frank T. Zenke et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR) Inhibitors
Kasun Wanigasooriya et al.
CANCERS (2020)
M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
Zhuo-Xun Wu et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
Tzu-Ting Huang et al.
CANCER TREATMENT REVIEWS (2020)
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
Shunsuke Kondo et al.
INVESTIGATIONAL NEW DRUGS (2020)
DNMT1 Enhances the Radiosensitivity of HPV-Positive Head and Neck Squamous Cell Carcinomas via Downregulating SMG1
Chunlin Zhang et al.
ONCOTARGETS AND THERAPY (2020)
The molecular basis and disease relevance of non-homologous DNA end joining
Bailin Zhao et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
Felix Burkel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth
Bing Zheng et al.
AGING-US (2020)
Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814
Qing Sun et al.
MOLECULAR CANCER RESEARCH (2019)
Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361
Way Wua Wong et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Oxidative Cyclization-Induced Activation of a Phosphoinositide 3-Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics
Haizhou Zhu et al.
CHEMMEDCHEM (2019)
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
Jacqueline H. L. Fok et al.
NATURE COMMUNICATIONS (2019)
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
Hannah C. Wise et al.
SCIENTIFIC REPORTS (2019)
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
Pamela Munster et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors
Ramon Salazar et al.
ONCOLOGIST (2018)
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Johanna C. Bendell et al.
CLINICAL CANCER RESEARCH (2018)
Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review
K. J. Jerzak et al.
CURRENT ONCOLOGY (2018)
The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts
Cindy R. Timme et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Inhibition of DNA-PK activity sensitizes A549 cells to X-ray irradiation by inducing the ATM-dependent DNA damage response
Lina Yang et al.
MOLECULAR MEDICINE REPORTS (2018)
VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells
Atif J. Khan et al.
Oncotarget (2018)
Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner
Katharina Mueck et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells
Long Cheng et al.
ONCOTARGET (2017)
CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
Toshiya Tsuji et al.
ONCOTARGET (2017)
Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity
S. Oeck et al.
SCIENTIFIC REPORTS (2017)
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
Emmanuel Seront et al.
BJU INTERNATIONAL (2016)
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia
Rachel Thijssen et al.
BLOOD (2016)
Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline
N. J. H. van Os et al.
CLINICAL GENETICS (2016)
Synthesis, structure elucidation, DNA-PK and PI3K and anti-cancer activity of 8-and 6-aryl-substituted-1-3-benzoxazines
Rick Morrison et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Michele C. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling
Tian Lan et al.
ONCOTARGET (2016)
Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells
Yun-fang Zhen et al.
ONCOTARGET (2016)
KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms
Min-Bin Chen et al.
ONCOTARGET (2016)
Dual Phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer
Yu-Hsuan Chen et al.
CANCER LETTERS (2015)
XLS (c9orf142) is a new component of mammalian DNA double-stranded break repair
A. Craxton et al.
CELL DEATH AND DIFFERENTIATION (2015)
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115
Deborah S. Mortensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair
Takashi Ochi et al.
SCIENCE (2015)
Interactome analysis identifies a new paralogue of XRCC4 in non-homologous end joining DNA repair pathway
Mengtan Xing et al.
NATURE COMMUNICATIONS (2015)
NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor
Lan Yu et al.
ONCOTARGET (2015)
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Carlos Rodrigo Gil del Alcazar et al.
CLINICAL CANCER RESEARCH (2014)
SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways
Evgenia Gubanova et al.
CELL CYCLE (2013)
1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity
Celine Cano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
Chris T. Williamson et al.
EMBO MOLECULAR MEDICINE (2012)
Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K
Joanne M. Munck et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
Bipasha Mukherjee et al.
NEOPLASIA (2012)
The RNA surveillance protein SMG1 activates p53 in response to DNA double-strand breaks but not exogenously oxidized mRNA
Jennifer S. Gewandter et al.
CELL CYCLE (2011)
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Luis I. Toledo et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
XLF Regulates Filament Architecture of the XRCC4.Ligase IV Complex
Michal Hammel et al.
STRUCTURE (2010)
Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase
Dexin Kong et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
Sarah E. Golding et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair
M-A Westhoff et al.
ONCOGENE (2009)
Radioprotection of 4-hydroxy-3,5-dimethoxybenzaldehyde (VND3207) in culture cells is associated with minimizing DNA damage and activating Akt
Hong Zheng et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
PKBα/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival
Lana Bozulic et al.
MOLECULAR CELL (2008)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
Synthesis and biological evaluation of pyrido[3′,2':4,5]furo [3,2-d]pyrimidine derivatives as novel PI3 kinase p110α inhibitors
Masahiko Hayakawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441
Yan Zhao et al.
CANCER RESEARCH (2006)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage
CM Sturgeon et al.
MOLECULAR CANCER THERAPEUTICS (2006)
XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining
P Ahnesorg et al.
CELL (2006)
Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly
D Buck et al.
CELL (2006)
Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach
IR Hardcastle et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
BP Nutley et al.
BRITISH JOURNAL OF CANCER (2005)
DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs
ET Shinohara et al.
CANCER RESEARCH (2005)
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage
J Falck et al.
NATURE (2005)
SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization
IH Ismail et al.
ONCOGENE (2004)
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
ZA Knight et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries
JJJ Leahy et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
I Hickson et al.
CANCER RESEARCH (2004)
A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia
E Willmore et al.
BLOOD (2004)
Requirement of the MRN complex for ATM activation by DNA damage
T Uziel et al.
EMBO JOURNAL (2003)
Vanillins - a novel family of DNA-PK inhibitors
S Durant et al.
NUCLEIC ACIDS RESEARCH (2003)
2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK)
JJ Hollick et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes
L Zou et al.
SCIENCE (2003)
Nbs1 promotes ATM dependent phosphorylation events including those required for G1/S arrest
PM Girard et al.
ONCOGENE (2002)
Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination
YM Ma et al.
CELL (2002)
Synthesis, crystal structure determination, and biological properties of the DNA-dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydrazonomethyl-5-(4-pyridyl)pyrid-[1H]-2-one (OK-1035)
M Stockley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
BHP Zhou et al.
NATURE CELL BIOLOGY (2001)
Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay
A Yamashita et al.
GENES & DEVELOPMENT (2001)
Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair
JR Walker et al.
NATURE (2001)
Cloning of a novel phosphatidylinositol kinase-related kinase - Characterization of the human SMG-1 RNA surveillance protein
G Denning et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency
D Moshous et al.
CELL (2001)
Both V(D)J recombination and radioresistance require DNA-PK kinase activity, though minimal levels suffice for V(D)J recombination
LJ Kienker et al.
NUCLEIC ACIDS RESEARCH (2000)
分享论文
